Also known as: FBS, bovine serum
Fetal Bovine Serum
Sourced from FDA-approved package inserts (DailyMed). Last verified: 2026-07-07.
What It Is & Why It's in Vaccines
Fetal bovine serum is a complex mixture of growth factors, proteins, and nutrients derived from the blood of bovine (cow) fetuses. It is widely used in cell culture as a growth supplement for the cell lines used to propagate vaccine viruses. It is not deliberately added to the final vaccine product — it is a residue from the cell culture medium, and most is removed during purification.
Not deliberately added — residual from cell culture medium. Vaccine viruses (measles, mumps, rubella, varicella, rabies, and others) are grown in animal cell lines that require fetal bovine serum as a growth supplement. The serum is removed during purification; trace protein residues may remain.
Dose-in-Context
Per-Dose Quantity
<1 ppm (parts per million) in purified products. The actual residual quantity in a 0.5 mL dose is on the order of nanograms.
Reference Comparison
Fetal bovine serum is a cell culture reagent, not a deliberate ingredient. The quantities present in the final vaccine are on the order of nanograms — several orders of magnitude below the threshold for any known biological effect. Regulatory standards (FDA, EMA, WHO) specify maximum allowable residual bovine serum albumin as a manufacturing quality marker.
Source: DailyMed package insert: M-M-R II. WHO Technical Report Series No. 941: Recommendations for the production and control of live attenuated influenza vaccines.
Route-of-Administration Note
Injected route. At nanogram quantities, residual fetal bovine serum proteins are rapidly cleared. The theoretical concern (bovine spongiform encephalopathy/prion transmission) has been addressed by sourcing FBS from countries with negligible BSE risk (New Zealand, Australia) and by the use of recombinant alternatives where possible.
Documented Adverse Effects
No established adverse effects have been attributed to residual fetal bovine serum at the trace quantities present in purified vaccines. The theoretical BSE concern has been addressed through sourcing requirements.
Bovine serum albumin allergy is recognized in individuals with beef allergy, but anaphylaxis to residual bovine serum in vaccines has not been documented as a specific clinical entity. The quantities are below the threshold for IgE-mediated reactions in the vast majority of beef-allergic individuals.
Vaccines Containing Fetal Bovine Serum
MMR — M-M-R II (Merck Sharp & Dohme LLC)
Live attenuated; no adjuvant. Product contains no preservative.
MMR — PRIORIX (GlaxoSmithKline Biologicals)
Contains no gelatin — relevant for gelatin allergy. Residual ovalbumin possible from chick-embryo manufacture.
Polio (IPV) — IPOL (Sanofi Pasteur)
Inactivated whole-virus; no aluminum adjuvant.
Varicella — Varivax (Merck Sharp & Dohme LLC)
Rotavirus — RotaTeq (Merck Sharp & Dohme LLC)
Hepatitis A — Vaqta (Merck Sharp & Dohme LLC)
Japanese Encephalitis — Ixiaro (Valneva Austria GmbH)
ⓘ Methodology Disclaimer: Ingredient lists are sourced from official FDA-approved package inserts for the specific branded products named on each vaccine page. Formulations can change between manufacturing lots and over time — always verify against the current package insert before making a clinical decision. The presence of a substance in a vaccine does not by itself indicate harm; toxicology is dose-, route-, and context-dependent. Comparisons to reference exposure levels are provided with their sources where available, and are approximate — see the cited source for full methodology.